ImmuPharma plc (FRA:25I)

Germany flag Germany · Delayed Price · Currency is EUR
0.0770
+0.0025 (3.36%)
Last updated: Feb 23, 2026, 8:21 AM CET
Market Cap48.94M +102.9%
Revenue (ttm)n/a
Net Income-4.59M
EPS-0.01
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume586
Open0.0770
Previous Close0.0745
Day's Range0.0770 - 0.0770
52-Week Range0.0005 - 0.2180
Betan/a
RSI52.39
Earnings DateApr 24, 2026

About ImmuPharma

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired aut... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 6
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 25I
Full Company Profile

Financial Performance

Financial numbers in GBP Financial Statements